David Frederick

1.6k total citations
33 papers, 1.2k citations indexed

About

David Frederick is a scholar working on Epidemiology, Hepatology and Cellular and Molecular Neuroscience. According to data from OpenAlex, David Frederick has authored 33 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Epidemiology, 16 papers in Hepatology and 8 papers in Cellular and Molecular Neuroscience. Recurrent topics in David Frederick's work include Hepatitis B Virus Studies (16 papers), Hepatitis C virus research (16 papers) and Neurotransmitter Receptor Influence on Behavior (8 papers). David Frederick is often cited by papers focused on Hepatitis B Virus Studies (16 papers), Hepatitis C virus research (16 papers) and Neurotransmitter Receptor Influence on Behavior (8 papers). David Frederick collaborates with scholars based in United States, Germany and France. David Frederick's co-authors include Merle G. Paule, Franck Rousseau, Michael Gillam, Patrick Marcellin, Ting‐Tsung Chang, Katyna Borroto–Esoda, Myron J. Tong, Seng Gee Lim, William Sievert and Sarah Arterburn and has published in prestigious journals such as Gastroenterology, Hepatology and Clinical Infectious Diseases.

In The Last Decade

David Frederick

33 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Frederick United States 18 774 753 221 129 116 33 1.2k
Lowell A. Borgen United States 11 366 0.5× 50 0.1× 97 0.4× 73 0.6× 14 0.1× 17 894
W Lowenstein France 13 133 0.2× 12 0.0× 148 0.7× 96 0.7× 65 0.6× 49 596
Pierre Dujols France 12 95 0.1× 45 0.1× 115 0.5× 11 0.1× 35 0.3× 21 607
Scott L. Letendre United States 13 130 0.2× 63 0.1× 34 0.2× 15 0.1× 270 2.3× 32 656
Alejandro Orrico‐Sánchez Spain 13 183 0.2× 33 0.0× 105 0.5× 6 0.0× 91 0.8× 42 456
Kreek Mj United States 12 109 0.1× 14 0.0× 152 0.7× 31 0.2× 35 0.3× 27 439
Coleen Hall United States 11 483 0.6× 357 0.5× 79 0.4× 87 0.8× 18 927
Pilar Rubio Spain 10 53 0.1× 88 0.1× 119 0.5× 2 0.0× 102 0.9× 13 338
Robert Gianotti United States 9 68 0.1× 22 0.0× 135 0.6× 3 0.0× 36 0.3× 14 462
Lisa McCall United States 8 152 0.2× 8 0.0× 132 0.6× 24 0.2× 55 0.5× 10 576

Countries citing papers authored by David Frederick

Since Specialization
Citations

This map shows the geographic impact of David Frederick's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Frederick with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Frederick more than expected).

Fields of papers citing papers by David Frederick

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Frederick. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Frederick. The network helps show where David Frederick may publish in the future.

Co-authorship network of co-authors of David Frederick

This figure shows the co-authorship network connecting the top 25 collaborators of David Frederick. A scholar is included among the top collaborators of David Frederick based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Frederick. David Frederick is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jonas, Maureen M., Déirdre Kelly, Henry Pollack, et al.. (2012). Efficacy and Safety of Long-term Adefovir Dipivoxil Therapy in Children With Chronic Hepatitis B Infection. The Pediatric Infectious Disease Journal. 31(6). 578–582. 15 indexed citations
2.
Shiffman, Mitchell L., Stanislas Pol, Lionel Rostaing, et al.. (2010). Efficacy and Pharmacokinetics of Adefovir Dipivoxil Liquid Suspension in Patients With Chronic Hepatitis B and Renal Impairment. The Journal of Clinical Pharmacology. 51(9). 1293–1301. 8 indexed citations
3.
Berg, Thomas, Patrick Marcellin, Fabien Zoulim, et al.. (2010). Tenofovir Is Effective Alone or With Emtricitabine in Adefovir-Treated Patients With Chronic-Hepatitis B Virus Infection. Gastroenterology. 139(4). 1207–1217.e3. 115 indexed citations
4.
Manns, M.P., Jenny Heathcote, Patrick Marcellin, et al.. (2010). 1017 EFFICACY OF TENOFOVIR DF TREATMENT IN PATIENTS WITH A SUBOPTIMAL RESPONSE TO ADEFOVIR DIPIVOXIL. Journal of Hepatology. 52. S393–S393. 2 indexed citations
5.
Wu, I‐Chin, Mitchell L. Shiffman, Myron J. Tong, et al.. (2008). Sustained Hepatitis B e Antigen Seroconversion in Patients with Chronic Hepatitis B after Adefovir Dipivoxil Treatment: Analysis of Precore and Basal Core Promoter Mutants. Clinical Infectious Diseases. 47(10). 1305–1311. 14 indexed citations
6.
Berg, Thomas, Bjarne Kuno Møller, G Gerken, et al.. (2008). Tenofovir disoproxil fumarate (TDF) versus Emtricitabine plus TDF for treatment of chronic Hepatitis B (CHB) in subjects with persistent viral replication receiving Adefovir dipivoxil (ADV). Zeitschrift für Gastroenterologie. 46(9). 6 indexed citations
7.
Sokal, Étienne, et al.. (2008). The Pharmacokinetics and Safety of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B Virus Infection. The Journal of Clinical Pharmacology. 48(4). 512–517. 16 indexed citations
8.
Jonas, Maureen M., Déirdre Kelly, Henry Pollack, et al.. (2008). Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology. 47(6). 1863–1871. 66 indexed citations
9.
Marcellin, Patrick, Ting‐Tsung Chang, Seng Gee Lim, et al.. (2008). Long-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen–positive chronic hepatitis B. Hepatology. 48(3). 750–758. 235 indexed citations
10.
11.
Sokal, Étienne, D. Kelly, Henry Pollack, et al.. (2007). Safety, efficacy and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to < 18) with chronic hepatitis B. Journal of Pediatric Gastroenterology and Nutrition. 44. 28–28. 2 indexed citations
12.
Bowyer, John F., John F. Young, William Slikker, et al.. (2003). Plasma Levels of Parent Compound and Metabolites after Doses of Either d-Fenfluramine or d-3,4-Methylenedioxymethamphetamine (MDMA) that Produce Long-Term Serotonergic Alterations. NeuroToxicology. 24(3). 379–390. 31 indexed citations
13.
Frederick, David, et al.. (1998). Acute Effects of Dexfenfluramine (d‐FEN) and Methylenedioxymethamphetamine (MDMA) before and after Short‐Course, High‐Dose Treatment. Annals of the New York Academy of Sciences. 844(1). 183–190. 24 indexed citations
14.
Frederick, David & Merle G. Paule. (1997). Effects of MDMA on Complex Brain Function in Laboratory Animals. Neuroscience & Biobehavioral Reviews. 21(1). 67–78. 45 indexed citations
15.
Frederick, David, Michael Gillam, Shelly Lensing, & Merle G. Paule. (1997). Acute Effects of LSD on Rhesus Monkey Operant Test Battery Performance. Pharmacology Biochemistry and Behavior. 57(4). 633–641. 15 indexed citations
16.
Frederick, David. (1996). Effects of selective dopamine D1- and D2-agonists and antagonists on timing performance in rats. Pharmacology Biochemistry and Behavior. 53(4). 759–764. 39 indexed citations
17.
Binienda, Zbigniew, David Frederick, Sherry A. Ferguson, et al.. (1995). The effects of perinatal hypoxia on the behavioral, neurochemical, and neurohistological toxicity of the metabolic inhibitor 3-nitropropionic acid. Metabolic Brain Disease. 10(4). 269–282. 21 indexed citations
18.
Frederick, David, Gene E. Schulze, Michael Gillam, & Merle G. Paule. (1995). Acute effects of physostigmine on complex operant behavior in rhesus monkeys. Pharmacology Biochemistry and Behavior. 50(4). 641–648. 20 indexed citations
19.
Frederick, David, Michael Gillam, Richard R. Allen, & Merle G. Paule. (1995). Acute behavioral effects of phencyclidine on rhesus monkey performance in an operant test battery. Pharmacology Biochemistry and Behavior. 52(4). 789–797. 36 indexed citations
20.
Frederick, David, et al.. (1990). Three new blood groups of rhesus monkeys. American Journal of Primatology. 20(2). 127–131. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Lowell A. Borgen Breakdown of academic impact, for papers by W Lowenstein Breakdown of academic impact, for papers by Pierre Dujols Breakdown of academic impact, for papers by Scott L. Letendre Breakdown of academic impact, for papers by Alejandro Orrico‐Sánchez Breakdown of academic impact, for papers by Kreek Mj Breakdown of academic impact, for papers by Coleen Hall Breakdown of academic impact, for papers by Pilar Rubio Breakdown of academic impact, for papers by Robert Gianotti Breakdown of academic impact, for papers by Lisa McCall
Rankless by CCL
2026